News
Source: NASDAQ
- EyePoint Pharmaceuticals Reports Fiscal Period Ended December 31, 2018 Financial Results and Highlights Recent Clinical and Operational Developments
- EyePoint Pharmaceuticals Announces U.S. Commercial Launch of DEXYCU (dexamethasone intraocular suspension) 9%
- EyePoint Pharmaceuticals Announces Fiscal Period Ended December 31, 2018 Financial Results Release Date and Conference Call Information
- EyePoint Pharmaceuticals Secures Up to $60 Million Debt Facility
- EyePoint Pharmaceuticals Announces U.S. Commercial Launch of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg
- EyePoint Pharmaceuticals Appoints David Guyer, M.D., to Board of Directors
- EyePoint Pharmaceuticals Provides 2019 Commercial Update
- EyePoint Pharmaceuticals Added to NASDAQ Biotechnology Index
- EyePoint Pharmaceuticals Appoints Ron Honig, Esq., as SVP, General Counsel & Company Secretary
- EyePoint Pharmaceuticals Announces Assignment of Permanent J-Code for DEXYCU™ by the Center for Medicare and Medicaid Services (CMS)
- EyePoint Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference
- EyePoint Pharmaceuticals Reports Fiscal First Quarter 2019 Financial Results and Highlights Recent Clinical and Operational Developments
- EyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize Durasert™ Three-Year Treatment for Posterior Segment Uveitis in the Greater China Region
- EyePoint Pharmaceuticals Announces First Quarter Fiscal Year 2019 Financial Results Release Date and Conference Call Information
- EyePoint Pharmaceuticals Appoints John Landis, Ph.D., M.S., to Board of Directors